Matinas BioPharma announces one-for-fifteen reverse stock split approval
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) has approved a one-for-fifteen reverse stock split of its common stock. The change will take effect at 12:01 a.m. Eastern Time on September 28, 2026, and the split-adjusted shares will begin trading on the NYSE American on that date. Following the split, each existing share will be converted to one new share, with no fractional shares issued and stockholders of fractional shares receiving a proportional cash payment instead.
The reverse split will not impact par value or the total authorized shares of common or preferred stock, and stockholders' percentage ownership and voting rights will remain unchanged. The new CUSIP number for the split-adjusted shares will be 576810 402. Matinas BioPharma's stock has declined over 90% in the past year and is trading near its 52-week low of $0.15.
The company has been working to regain compliance with NYSE American listing standards, currently lacking a minimum stockholders' equity of $4.0 million as of March 31, 2026.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
